Search

Your search keyword '"G. van Lijnschoten"' showing total 4 results
Start Over Author "G. van Lijnschoten" Journal annals of surgical oncology
4 results on '"G. van Lijnschoten"'

1. Improved Outcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer

Author

E L K, Voogt, D M G I, van Zoggel, M, Kusters, G A P, Nieuwenhuijzen, J G, Bloemen, H M U, Peulen, G J M, Creemers, G, van Lijnschoten, J, Nederend, M J, Roef, J W A, Burger, and H J T, Rutten

Subjects
Male, Reoperation, Proctectomy, Organoplatinum Compounds, Rectal Neoplasms, Leucovorin, Margins of Excision, Induction Chemotherapy, Middle Aged, Combined Modality Therapy, Survival Analysis, Neoadjuvant Therapy, Oxaliplatin, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Fluorouracil, Neoplasm Recurrence, Local, Capecitabine, Aged, Retrospective Studies
Abstract

Despite improvements in the multimodality treatment for patients with locally recurrent rectal cancer (LRRC), oncological outcomes remain poor. This study evaluated the effect of induction chemotherapy and subsequent chemo(re)irradiation on the pathologic response and the rate of resections with clear margins (R0 resection) in relation to long-term oncological outcomes.All consecutive patients with LRRC treated in the Catharina Hospital Eindhoven who underwent a resection after treatment with induction chemotherapy and subsequent chemo(re)irradiation between January 2010 and December 2018 were retrospectively reviewed. Induction chemotherapy consisted of CAPOX/FOLFOX. Endpoints were pathologic response, resection margin and overall survival (OS), disease free survival (DFS), local recurrence free survival (LRFS), and metastasis free survival (MFS).A pathologic complete response was observed in 22 patients (17%), a "good" response (Mandard 2-3) in 74 patients (56%), and a "poor" response (Mandard 4-5) in 36 patients (27%). An R0 resection was obtained in 83 patients (63%). The degree of pathologic response was linearly correlated with the R0 resection rate (p = 0.026). In patients without synchronous metastases, pathologic response was an independent predictor for LRFS, MFS, and DFS (p = 0.004, p = 0.003, and p = 0.024, respectively), whereas R0 resection was an independent predictor for LRFS and OS (p = 0.020 and p = 0.028, respectively).Induction chemotherapy in addition to neoadjuvant chemo(re)irradiation is a promising treatment strategy for patients with LRRC with high pathologic response rates that translate into improved oncological outcomes, especially when an R0 resection has been achieved.

Published
2019

2. A Highly Active and Tolerable Neoadjuvant Regimen Combining Paclitaxel, Carboplatin, 5-FU, and Radiation Therapy in Patients with Stage II and III Esophageal Cancer

Author

H.J.T. Rutten, M.J.C. van der Sangen, G.J.M. Creemers, G. van Lijnschoten, G.A.P. Nieuwenhuijzen, O. J. Repelaer van Driel, L. van de Schoot, and E. A. P. M. Romme

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Esophageal Neoplasms, Paclitaxel, medicine.medical_treatment, Esophageal cancer, Phases of clinical research, Adenocarcinoma, Disease-Free Survival, Carboplatin, Tumor regression grade, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Pathologic complete response, Humans, Medicine, Prospective Studies, Neoadjuvant therapy, Aged, Neoplasm Staging, Gastrointestinal Oncology, business.industry, Remission Induction, Middle Aged, medicine.disease, Combined Modality Therapy, Neoadjuvant Therapy, Neoadjuvant chemoradiation, Survival Rate, Radiation therapy, Regimen, Treatment Outcome, chemistry, Carcinoma, Squamous Cell, Feasibility Studies, Female, Surgery, Fluorouracil, business
Abstract

Background The present phase II study aimed to assess the feasibility and efficacy of a new paclitaxel-based neoadjuvant chemoradiation regimen followed by surgery in patients with stage II–III esophageal cancer. Methods From January 2002 to November 2004, 50 patients with a potentially resectable stage II–III esophageal cancer received chemotherapy with paclitaxel, carboplatin, and 5-FU in combination with radiotherapy 45 Gy in 25 fractions. Surgery followed 6–8 weeks after completion of neoadjuvant treatment. Results Patient characteristics: male/female: 44/6, median age 60 years (34–75), median WHO 1 (0–2), adenocarcinoma (n = 42), squamous cell carcinoma (n = 8). Toxicity was mild, and 84 % of the patients completed the whole regimen. Forty-seven patients underwent surgery with a curative intention (transhiatal n = 44, transthoracic n = 3). Pathologic complete tumor regression was achieved in 18 of 47 operated patients (38%). R0 resection was achieved in 45 of 47 operated patients (96%). There were four postoperative deaths (8.5). Postoperative complications were comparable with other studies. After a median follow-up of 41.5 months (21–59) estimated 3- and 5-year survival on an intention-to-treat basis was 56 and 48%. Estimated 3-year survival in responders was 61%, in nonresponders 33%. Conclusion This novel neoadjuvant chemoradiation regimen for treatment of patients with stage II–III esophageal cancer is feasible. Results are encouraging with a high pathologic complete tumor regression and R0 resection rate and an acceptable morbidity and mortality. Preliminary survival data are very promising.

Full Text
View/download PDF

3. Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC).

Author

Rovers KP, Wassenaar ECE, Lurvink RJ, Creemers GM, Burger JWA, Los M, Huysentruyt CJR, van Lijnschoten G, Nederend J, Lahaye MJ, Deenen MJ, Wiezer MJ, Nienhuijs SW, Boerma D, and de Hingh IHJT

Subjects
Aerosols, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Oxaliplatin therapeutic use, Colorectal Neoplasms drug therapy, Peritoneal Neoplasms drug therapy
Abstract

Background: Despite its increasing use, pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) has never been prospectively investigated as a palliative monotherapy for colorectal peritoneal metastases in clinical trials. This trial aimed to assess the safety (primary aim) and antitumor activity (key secondary aim) of PIPAC-OX monotherapy in patients with unresectable colorectal peritoneal metastases., Methods: In this two-center, single-arm, phase II trial, patients with isolated unresectable colorectal peritoneal metastases in any line of palliative treatment underwent 6-weekly PIPAC-OX (92 mg/m 2 ). Key outcomes were major treatment-related adverse events (primary outcome), minor treatment-related adverse events, hospital stay, tumor response (radiological, biochemical, pathological, ascites), progression-free survival, and overall survival., Results: Twenty enrolled patients underwent 59 (median 3, range 1-6) PIPAC-OX procedures. Major treatment-related adverse events occurred in 3 of 20 (15%) patients after 5 of 59 (8%) procedures (abdominal pain, intraperitoneal hemorrhage, iatrogenic pneumothorax, transient liver toxicity), including one possibly treatment-related death (sepsis of unknown origin). Minor treatment-related adverse events occurred in all patients after 57 of 59 (97%) procedures, the most common being abdominal pain (all patients after 88% of procedures) and nausea (65% of patients after 39% of procedures). Median hospital stay was 1 day (range 0-3). Response rates were 0% (radiological), 50% (biochemical), 56% (pathological), and 56% (ascites). Median progression-free and overall survival were 3.5 months (interquartile range [IQR] 2.5-5.7) and 8.0 months (IQR 6.3-12.6), respectively., Conclusions: In patients with unresectable colorectal peritoneal metastases undergoing PIPAC-OX monotherapy, some major adverse events occurred and minor adverse events were common. The clinical relevance of observed biochemical, pathological, and ascites responses remains to be determined, especially since radiological response was absent., (© 2021. Society of Surgical Oncology.)

Published
2021
Full Text
View/download PDF

4. Improved Outcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer.

Author

Voogt ELK, van Zoggel DMGI, Kusters M, Nieuwenhuijzen GAP, Bloemen JG, Peulen HMU, Creemers GJM, van Lijnschoten G, Nederend J, Roef MJ, Burger JWA, and Rutten HJT

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Capecitabine administration & dosage, Combined Modality Therapy, Female, Fluorouracil administration & dosage, Humans, Leucovorin administration & dosage, Male, Margins of Excision, Middle Aged, Organoplatinum Compounds administration & dosage, Oxaliplatin administration & dosage, Proctectomy methods, Reoperation, Retrospective Studies, Survival Analysis, Treatment Outcome, Induction Chemotherapy methods, Neoadjuvant Therapy methods, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local radiotherapy, Neoplasm Recurrence, Local surgery, Rectal Neoplasms drug therapy, Rectal Neoplasms mortality, Rectal Neoplasms radiotherapy, Rectal Neoplasms surgery
Abstract

Background: Despite improvements in the multimodality treatment for patients with locally recurrent rectal cancer (LRRC), oncological outcomes remain poor. This study evaluated the effect of induction chemotherapy and subsequent chemo(re)irradiation on the pathologic response and the rate of resections with clear margins (R0 resection) in relation to long-term oncological outcomes., Methods: All consecutive patients with LRRC treated in the Catharina Hospital Eindhoven who underwent a resection after treatment with induction chemotherapy and subsequent chemo(re)irradiation between January 2010 and December 2018 were retrospectively reviewed. Induction chemotherapy consisted of CAPOX/FOLFOX. Endpoints were pathologic response, resection margin and overall survival (OS), disease free survival (DFS), local recurrence free survival (LRFS), and metastasis free survival (MFS)., Results: A pathologic complete response was observed in 22 patients (17%), a "good" response (Mandard 2-3) in 74 patients (56%), and a "poor" response (Mandard 4-5) in 36 patients (27%). An R0 resection was obtained in 83 patients (63%). The degree of pathologic response was linearly correlated with the R0 resection rate (p = 0.026). In patients without synchronous metastases, pathologic response was an independent predictor for LRFS, MFS, and DFS (p = 0.004, p = 0.003, and p = 0.024, respectively), whereas R0 resection was an independent predictor for LRFS and OS (p = 0.020 and p = 0.028, respectively)., Conclusions: Induction chemotherapy in addition to neoadjuvant chemo(re)irradiation is a promising treatment strategy for patients with LRRC with high pathologic response rates that translate into improved oncological outcomes, especially when an R0 resection has been achieved.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results